Somatostatin inhibits the secretion of bombesin-like peptides from small cell lung cancer cells.
The effects of somatostatin (SRIF) on small cell lung cancer (SCLC) cell line NCI-H345 was investigated. SRIF had no effects on the basal cAMP levels or the secretion rate of bombesin-like peptides. VIP (1 microM) increased the cAMP levels approximately 10-fold and the secretion rate of bombesin-like peptides 3-fold. SRIF and its analogues inhibited the increase in the cAMP levels and the secretion rate of bombesin-like peptides caused by VIP. The order of peptide potency was (D-Trp8)SRIF > SRIF-28 = (Tyr11)SRIF > SRIF. These data suggest that functional SRIF receptors may be present on SCLC cells.
Kee
K A
KA
Department of Biochemistry, George Washington University School of Medicine and Health Sciences, Washington, DC 20037.
Finan
T M
TM
Korman
L Y
LY
Moody
T W
TW
D001839:Bombesin / Q000378:metabolism*; D018288:Carcinoma, Small Cell / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism; D008175:Lung Neoplasms / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism*; D011964:Receptors, Gastrointestinal Hormone / Q000378:metabolism; D018005:Receptors, Vasoactive Intestinal Peptide; D013004:Somatostatin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014660:Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors
D010455:Peptides; D011964:Receptors, Gastrointestinal Hormone; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D000242:Cyclic AMP; D001839:Bombesin